Radiolabeled COX-2 inhibitors for non-invasive visualization of COX-2 expression and activity - A critical update

Molecules

Volumn 18, Issue 6, 2013, Pages 6311-6355

  Laube, Markus ^a,b   Kniess, Torsten ^a   Pietzsch, Jens ^a,b  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Carbon 11; COXIB; Cyclooxygenase; Fluorine 18; Imaging; Inhibitor; NSAID; Radioiodine; Radionuclide; Visualization

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; RADIOPHARMACEUTICAL AGENT;

CHEMISTRY; GENE EXPRESSION; HISTORY; ISOTOPE LABELING; METABOLISM; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNTHESIS;

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; GENE EXPRESSION; HISTORY, 21ST CENTURY; ISOTOPE LABELING; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84879610402     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18066311     Document Type: Review

References (86)

1. Fu, J.Y.; Masferrer, J.L.; Seibert, K.; Raz, A.; Needleman, P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 1990, 265, 16737-16740.
2. Hawkey, C.J. COX-2 Chronology. Gut 2005, 54, 1509-1514.
3. de Vries, E.F. Imaging of cyclooxygenase-2 (COX-2) expression: Potential use in diagnosis and drug evaluation. Curr. Pharm. Des. 2006, 12, 3847-3856.
4. Smith, W.L.; DeWitt, D.L.; Garavito, R.M. CYCLOOXYGENASES: Structural, Cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69, 145.
5. van der Donk, W.A.; Tsai, A.; Kulmacz, R.J. The cyclooxygenase reaction mechanism. Biochemistry 2002, 41, 15451-15458.
6. Crofford, L.J.; Lipsky, P.E.; Brooks, P.; Abramson, S.B.; Simon, L.S.; van de Putte, L.B. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum. 2000, 43, 4-13.
7. Rouzer, C.A.; Marnett, L.J. Cyclooxygenases: Structural and functional insights. J. Lipid Res. 2009, 50, S29-34.
8. Sminia, P.; Kuipers, G.; Geldof, A.; Lafleur, V.; Slotman, B. COX-2 inhibitors act as radiosensitizer in tumor treatment. Biomed. Pharmacother. 2005, 59, S272-S275.
9. Marnett, L.J. Inflammation and Cancer: Chemical Approaches to Mechanisms, Imaging, and Treatment. J. Org. Chem. 2012, 77, 5224-5238.
10. Reinauer, C.; Censarek, P.; Kaber, G.; Weber, A.A.; Steger, G.; Klamp, T.; Schror, K. Expression and translation of the COX-1b gene in human cells - No evidence for generation of COX-1b protein. Biol. Chem. 2013, 394, 753-760.
11. Sobolewski, C.; Cerella, C.; Dicato, M.; Ghibelli, L.; Diederich, M. The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int. J. Cell. Biol. 2010, 2010, doi:10.1155/2010/215158.
12. Blobaum, A.L.; Marnett, L.J. Structural and functional basis of Cyclooxygenase inhibition. J. Med. Chem. 2007, 50, 1425-1441.
13. Marnett, L.J. The COXIB experience: A look in the rearview mirror. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 265-290.
14. Rao, R.; Knaus, E.E. Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond. J. Pharm. Pharm. Sci. 2008, 11, 81s-110s.
15. Peters, J.; Nel, D.; Adam, S. Reaching and influencing consumers in the prescription medicine market. Market Intell. Plann. 2009, 27, 909-925.
16. Jawabrah Al-Hourani, B.; Sharma, S.K.; Suresh, M.; Wuest, F. Cyclooxygenase-2 inhibitors: A literature and patent review (2009- 2010). Expert Opin. Ther. Pat. 2011, 21, 1339-1432.
17. Soumaoro, L.T.; Uetake, H.; Higuchi, T.; Takagi, Y.; Enomoto, M.; Sugihara, K. Cyclooxygenase-2 expression: A significant prognostic indicator for patients with colorectal cancer. Clin. Cancer Res. 2004, 10, 8465-8471.
18. Trojan, A.; Tinguely, M.; Vallet, S.; Seifert, B.; Jenni, B.; Zippelius, A.; Witzens-Harig, M.; Mechtersheimer, G.; Ho, A.; Goldschmidt, H.; et al. Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Med. Wkly. 2006, 136, 400-403.
19. Khuri, F.R.; Wu, H.; Lee, J.J.; Kemp, B.L.; Lotan, R.; Lippman, S.M.; Feng, L.; Hong, W.K.; Xu, X.C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 2001, 7, 861-867.
20. Costa, C.; Soares, R.; Reis-Filho, J.S.; Leitao, D.; Amendoeira, I.; Schmitt, F.C. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J. Clin. Pathol. 2002, 55, 429-434.
21. Nakamoto, R.H.; Uetake, H.; Iida, S.; Kolev, Y.V.; Soumaoro, L.T.; Takagi, Y.; Yasuno, M.; Sugihara, K. Correlations between Cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer. Jpn. J. Clin. Oncol. 2007, 37, 679-685.
22. Ghosh, N.; Chaki, R.; Mandal, V.; Mandal, S.C. COX-2 as a target for cancer chemotherapy. Pharmacol. Rep. 2010, 62, 233-244.
23. Wang, D.; DuBois, R.N. Eicosanoids and cancer. Nat. Rev. Cancer 2010, 10, 181-193.
24. Piazza, G.A.; Keeton, A.B.; Tinsley, H.N.; Whitt, J.D.; Gary, B.D.; Mathew, B.; Singh, R.; Grizzle, W.E.; Reynolds, R.C. NSAIDs: Old drugs reveal new anticancer targets. Pharmaceuticals 2010, 3, 1652-1667.
25. Cohen, B.L.; Gomez, P.; Omori, Y.; Duncan, R.C.; Civantos, F.; Soloway, M.S.; Lokeshwar, V.B.; Lokeshwar, B.L. Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int. J. Cancer 2006, 119, 1082-1087.
26. El-Bassiouny, A.E.; Zoheiry, M.M.; Nosseir, M.M.; El-Ahwany, E.G.; Ibrahim, R.A.; El- Bassiouni, N.E. Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma. MedGenMed 2007, 9, 45.
27. 18F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression. J. Nucl. Med. 2003, 44, 1700-1706.
28. 18F-labeled cyclooxygenase-2 (COX-2) inhibitor as a potential PET imaging agent. J. Labelled Compd. Radiopharmaceut. 2006, 49, 583-593.
29. 11C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. Nucl. Med. Biol. 2008, 35, 35-42.
30. 11C-labeled cyclooxygenase-2 (COX-2) inhibitor. Bioorg. Med. Chem. 2008, 16, 7662-7670.
31. 18F-labeled 2,3-diarylsubstituted indole via McMurry coupling for functional characterization of cyclooxygenase-2 (COX-2) in vitro and in vivo. Bioorg. Med. Chem. 2012, 20, 3410-3421.
32. 18F-labeled COX-1 and COX-2 inhibitors. J. Nucl. Med. 2002, 43, 117-124.
33. 18F]fluorinated analogue of valdecoxib, as a potential radiotracer for imaging cyclooxygenase-2 with positron emission tomography. Bioorg. Med. Chem. Lett. 2005, 15, 4699-4702.
34. 18F]labeled COX-2 inhibitors. In Proceedings of The 233rd ACS National Meeting, Chicago, IL, USA, 25-29 March, 2007; p. FLUO-014.
35. 11C-Labeled analogs of indomethacin esters and amides for brain cyclooxygenase-2 imaging: Radiosynthesis, in vitro evaluation and in vivo characteristics in mice. Chem. Pharm. Bull. 2011, 59, 938-946.
36. 11C-ketoprofen methyl ester. J. Nucl. Med. 2011, 52, 1094-1101.
37. Kniess, T.; Laube, M.; Bergmann, R.; Graf, F.; Steinbach, J.; Pietzsch, J. 2,3-Diaryl substituted indoles as probes for monitoring cyclooxygenase-2 (COX-2) with PET-radiolabeling, in vitro and in vivo studies. Nuklearmedizin 2012, 51, A11-A12.
38. Kuge, Y.; Shimonaka, S.; Katada, Y.; Temma, T.; Kimura, H.; Kiyono, Y.; Yokota, C.; Minematsu, K.K.; Seki, K.; Tamaki, N.; et al. Synthesis and evaluation of a radioiodinated coxib as a spect tracer for cyclooxygenase-2 expression. J. Labelled Compd. Radiopharm. 2005, 48, S297.
39. Kuge, Y.; Katada, Y.; Shimonaka, S.; Temma, T.; Kimura, H.; Kiyono, Y.; Yokota, C.; Minematsu, K.; Seki, K.; Tamaki, N.; et al. Synthesis and evaluation of radioiodinated cyclooxygenase-2 inhibitors as potential SPECT tracers for cyclooxygenase-2 expression. Nucl. Med. Biol. 2006, 33, 21-27.
40. 11C]diclofenac sodium: synthesis and PET assessment of transdermal penetration. Nucl. Med. Biol. 2011, 38, 181-189.
41. 18F]fluoroiodobenzene as radiotracers for positron emission tomography (PET). Org. Biomol. Chem. 2005, 3, 503-507.
42. 11C]methylsulfones: potential PET probes for imaging cyclooxygenase-2 expression. Bioorg. Med. Chem. Lett. 2005, 15, 4268-4271.
43. 11C-labeled diaryl-substituted imidazole and indole derivatives for mapping cyclooxygenase-2. Biol. Pharm. Bull. 2006, 29, 2087-2094.
44. 18F]-4-[5-(4- methylphenyl)-3-(trifluoromethyl)-1H- pyrazol-1-yl]benzenesulfonamide as a PET imaging probe for COX-2 expression. Bioorg. Med. Chem. 2007, 15, 1802-1807.
45. 11C-labeling of 2-arylpropionic acids and their esters: Construction of a PET tracer library for a study of biological events involved in COXs expression. Chem. Eur. J. 2010, 16, 4250-4258.
46. Gao, M.; Wang, M.; Miller, K.D.; Zheng, Q. Synthesis and preliminary in vitro biological evaluation of new carbon-11-labeled celecoxib derivatives as candidate PET tracers for imaging of COX-2 expression in cancer. Eur. J. Med. Chem. 2011, 46, 4760-4767.
47. 11C]-TMI: A Potential PET Tracer for Imaging COX-2 Expression. In Proceedings of the 228th ACS National Meeting, Philadelphia, PA, USA, 22-26 August, 2004; p. MEDI-244.
48. Uddin, M.J.; Crews, B.C.; Ghebreselasie, K.; Huda, I.; Kingsley, P.J.; Ansari, M.S.; Tantawy, M.N.; Reese, J.J.; Marnett, L.J. Fluorinated cyclooxygenase-2 inhibitors as agents in PET imaging of inflammation and cancer. Cancer Prev. Res. 2011, 4, 1536-1545.
49. Uddin, M.J.; Crews, B.C.; Blobaum, A.L.; Kingsley, P.J.; Ghebreselasie, K.; Saleh, S.S.; Clanton, J.A.; Baldwin, R.M.; Marnett, L.J. Synthesis and ealuation of [123I]-indomethacin derivatives as COX-2 targeted imaging agents. J. Labelled Compd. Radiopharm. 2009, 52, 387-393.
50. 123I]-Celecoxib analogues as spect tracers of cyclooxygenase-2 in inflammation. ACS Med. Chem. Lett. 2011, 2, 160-164.
51. 11C-labeled 1,5-diarylpyrazole derivatives for mapping cyclooxygenases. Ann. Nucl. Med. 2005, 19, 617-625.
52. Kabalka, G.W.; Mereddy, A.R.; Schuller, H.M. Synthesis of an iodine-123-labeled celecoxib analogue: a potential spect agent. J. Labelled Compd. Radiopharm. 2005, 48, 295-300.
53. Schuller, H.M.; Kabalka, G.; Smith, G.; Mereddy, A.; Akula, M.; Cekanova, M. Detection of Overexpressed COX-2 in precancerous lesions of hamster pancreas and lungs by molecular imaging: Implications for early diagnosis and prevention. ChemMedChem 2006, 1, 603-610.
54. 99mTc-labeled celebrex. Anticancer Drugs 2004, 15, 255-263.
55. Shimizu, K.; Hirami, Y.; Saisho, S.; Yukawa, T.; Maeda, A.; Yasuda, K.; Nakata, M. Maximal standardized uptake value on FDG-PET is correlated with cyclooxygenase-2 expression in patients with lung adenocarcinoma. Ann. Thorac. Surg. 2012, 93, 398-403.
56. 11C] plyhomoallylic fatty acids. J. Labelled Compd. Radiopharm. 1993, 33, 541-546.
57. Rapoport, S.I. In vivo approaches to quantifying and imaging brain arachidonic and docosahexaenoic acid metabolism. J. Pediatr. 2003, 143, 26-34.
58. 11C]indomethacin methyl ester for in vivo brain studies of cyclooxygenase-2. J. Nucl. Med. 1996, 37, 192P.
59. 99mTc-diflunisal and the human iris: Topical application reveals localization. J. Ocul. Pharmacol. Ther. 2002, 18, 185-195.
60. 11C]-Celecoxib: A Potential PET tracer for imaging COX-2 Expression. In Proceedings of the 226th ACS National Meeting, New York, NY, USA, 7-11 September, 2003; p. MEDI-375.
61. 11C]celecoxib: A potential PET probe for imaging COX-2 expression. J. Labelled Compd. Radiopharm. 2005, 48, 887-895.
62. Penning, T.D.; Talley, J.J.; Bertenshaw, S.R.; Carter, J.S.; Collins, P.W.; Docter, S.; Graneto, M.J.; Lee, L.F.; Malecha, J.W.; Miyashiro, J.M.; et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)- 3(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (Sc-58635, celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
63. Kawamura, K.; Fujisaki, Y.; Ishiwata, K.; Yamamoto, F.; Maeda, M. Efficient O-[C- 11]Methylation with [C-11]methyl triflate: Synthesis of C-11-labeled diaryl substituted pyrazole and imidazole cyclooxygenase inhibitors. J. Labelled Compd. Radiopharm. 2005, 48, S206.
64. Almansa, C.; Alfón, J.; de Arriba, A.F.; Cavalcanti, F.L.; Escamilla, I.; Gómez, L.A.; Miralles, A.; Soliva, R.; Bartrolí, J.; Carceller, E.; et al. Synthesis and structure-Activity relationship of a new series of COX-2 selective inhibitors: 1,5-Diarylimidazoles. J. Med. Chem. 2003, 46, 3463-3475.
65. Praveen Rao, P.N.; Amini, M.; Li, H.; Habeeb, A.G.; Knaus, E.E. Design, Synthesis, And biological evaluation of 6-Substituted-3-(4- methanesulfonylphenyl)-4-phenylpyran-2-ones: A novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. J. Med. Chem. 2003, 46, 4872-4882.
66. Hu, W.; Guo, Z.; Chu, F.; Bai, A.; Yi, X.; Cheng, G.; Li, J. Synthesis and biological evaluation of substituted 2-sulfonyl-phenyl-3-phenyl-indoles: A new series of selective COX-2 inhibitors. Bioorg. Med. Chem. 2003, 11, 1153-1160.
67. de Vries, E.F.J.; Doorduin, J.; Vellinga, N.A.R.; van Waarde, A.; Dierckx, R.A.; Klein, H.C. Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study. Nucl. Med. Biol. 2008, 35, 459-466.
68. 11C] methylation using an organoboron precursor and pet imaging of COX-2 expression in rat brains. J. Labelled Compd. Radiopharm. 2009, 52, S435.
69. Riendeau, D.; Salem, M.; Styhler, A.; Ouellet, M.; Mancini, J.A.; Li, C.S. Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2. Bioorg. Med. Chem. Lett. 2004, 14, 1201-1203.
70. Warner, T.D.; Giuliano, F.; Vojnovic, I.; Bukasa, A.; Mitchell, J.A.; Vane, J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. USA 1999, 96, 7563-7568.
71. 11C-labeled ibuprofen. Tetrahedron Lett. 2010, 51, 5908-5911.
72. 11C-labeled ibuprofen assisted by DMSO for imaging of in vivo behavior of the individual isomers by positron emission tomography. Bioorg. Med. Chem. 2011, 19, 3265-3273.
73. Al-Hourani, B.J.; Sharma Sai, K.; Wang, M.; Suresh, M.; Wuest, F. Synthesis and radiopharmacological evaluation of F-18-labeled peptides for targeting COX-2. J. Labelled Compd. Radiopharm. 2011, 54, S203.
74. Sharma, S.K.; Al-Hourani, B.J.; Wuest, M.; Mane, J.Y.; Tuszynski, J.; Baracos, V.; Suresh, M.; Wuest, F. Synthesis and evaluation of fluorobenzoylated di- and tripeptides as inhibitors of cyclooxygenase-2 (COX-2). Bioorg. Med. Chem. 2012, 20, 2221-2226.
75. 11C]SC-62807 and in vivo PET evaluation. Bioorg. Med. Chem. 2011, 19, 2997-3004.
76. Kalgutkar, A.S.; Marnett, A.B.; Crews, B.C.; Remmel, R.P.; Marnett, L.J. Ester and Amide Derivatives of the Nonsteroidal Antiinflammatory Drug, Indomethacin, as Selective Cyclooxygenase-2 Inhibitors. J. Med. Chem. 2000, 43, 2860-2870.
77. 18F-labeling-radiosynthesis of a 2,3-diarylsubstituted COX-2 inhibitor. J. Labelled Compd. Radiopharm. 2011, 54, S73.
78. 18F-labelled compounds via nitrile oxide cycloadditions. Chem. Commun. 2012, 48, 7134-7136.
79. Uddin, M.J.; Crews, B.C.; Blobaum, A.L.; Kingsley, P.J.; Gorden, D.L.; McIntyre, J.O.; Matrisian, L.M.; Subbaramaiah, K.; Dannenberg, A.J.; Piston, D.W.; et al. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res. 2010, 70, 3618-3627.
80. Kuge, Y.; Obokata, N.; Kimura, H.; Katada, Y.; Temma, T.; Sugimoto, Y.; Aita, K.; Seki, K.; Tamaki, N.; Saji, H. Synthesis and evaluation of a radioiodinated lumiracoxib derivative for the imaging of cyclooxygenase-2 expression. Nucl. Med. Biol. 2009, 36, 869-876.
81. El-Azony, K. Preparation of 125I-celecoxib with high purity as a possible tumor agent. J. Radioanal. Nucl. 2010, 285, 315-320.
82. Zlatopolskiy, B.D.; Vogg, A.; Neumaier, B.; Mottaghy, F.M.; Morgenroth, A. Radioiodinated Indometacin Amides as COX-2-Specific Tracers: Synthesis and Initial in Vitro Study. Eur. J. Nucl. Med. Mol. Imaging 2012, 39, S216.
83. Yadav, M.R.; Pawar, V.P.; Marvaniya, S.M.; Halen, P.K.; Giridhar, R.; Mishra, A.K. Site specific chemical delivery of NSAIDs to inflamed joints: Synthesis, Biological activity and γ-imaging studies of quaternary ammonium salts of tropinol esters of some NSAIDs or their active metabolites. Bioorg. Med. Chem. 2008, 16, 9443-9449.
84. Yadav, M.; Giridhar, R.; Tamboli, R.; Pawar, V.; Gohil, V. Cartilage targeted chemical delivery of naproxen and ibuprofen for the treatment of arthritis. J. Pharm. Bioall. Sci. 2012, 4, 10-11.
85. 99mTc-celecoxib and its biological evaluation. J. Radioanal. Nucl. 2011, 290, 685-690.
86. Abdellatif, K.R.A.; Velázquez, C.A.; Huang, Z.; Chowdhury, M.A.; Knaus, E.E. Triaryl (Z)-olefins suitable for radiolabeling with carbon-11 or fluorine-18 radionuclides for positron emission tomography imaging of cyclooxygenase-2 expression in pathological disease. Bioorg. Med. Chem. Lett. 2010, 20, 5245-5250.